retatrutide news recency 3 🚨Breaking: Retatrutide's first Phase T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending First Retatrutide phase 3 data,

Some patients report reduced hunger and earlier satiety within the first week of GLP-1 treatment, though individual response varies considerably

The data we have comes largely from comparing separate trial populations, which introduces variables like differences in baseline BMI, diet and exercise protocols, and participant demographics

Weight regain is common after stopping GLP-1 medication, particularly if appetite returns fully and no maintenance habits are in place

Shelf life: Compounded semaglutide is typically formulated without stabilizers, so it has a shorter shelf life than brand-name products, normally 30 to 90 days

And here, the differences between dual and triple agonism create meaningfully different benefit profiles

AICAR significantly promoted cell viability and inhibited the cell apoptosis in INS-1 cells, while PARP-1 exerted opposite effects